Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition
World Nutrition, 2019 There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2020 Traumatic brain injury (TBI) is a commonly occurring injury in sports, victims of motor vehicle accidents, and falls. TBI has become a pressing public health concern with no specific therapeutic treatment.
Miaad Bader +13 more
doaj +1 more source
Role of Fibre in Nutritional Management of Pancreatic Diseases [PDF]
, 2019 The role of fibre intake in the management of patients with pancreatic disease is still controversial. In acute pancreatitis, a prebiotic enriched diet is associated with low rates of pancreatic necrosis infection, hospital stay, systemic inflammatory ...
Badiali, Danilo +7 more
core +1 more source
Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin-Based Therapy and Referred or Not to a Weight Management Clinic: A Single-Center Retrospective Analyses. [PDF]
Obes Sci PractABSTRACT Background Incretin therapies yield strong metabolic improvements, but whether adding a weight‐management (WM) clinic confers additional benefit beyond pharmacotherapy alone in routine care is unclear. Objective Evaluate whether referral to WM clinic, alongside standard diabetes care, provides additional benefit for adults with type 2 diabetes
Robinson KM +5 more
europepmc +2 more sources
Cyclic AMP signalling in pancreatic islets [PDF]
, 2010 Cyclic 3'5'AMP (cAMP) is an important physiological amplifier of glucose-induced insulin secretion by the pancreatic islet β-cell, where it is formed by the activity of adenylyl cyclases, which are stimulated by glucose, through elevation in ...
Furman, Brian +2 more
core +1 more source
Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity
Periodontology 2000, EarlyView., 2023 Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti +2 more
wiley +1 more source
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Frontiers in Molecular Biosciences, 2023 Type 2 diabetes (T2D) and obesity have reached epidemic proportions. Incretin therapy is the second line of treatment for T2D, improving both blood glucose regulation and weight loss.
Gregory O. Austin, Alejandra Tomas
doaj +1 more source
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
Update on incretin hormones [PDF]
Annals of the New York Academy of Sciences, 2011 The incretin hormones glucagon‐like‐peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) are released from the intestine following oral ingestion of nutrients. Incretins promote insulin secretion, while GLP‐1 also inhibits glucagon release and gastric emptying, minimizing postprandial glucose excursions.
Phillips, Liza K., Prins, Johannes B.
openaire +3 more sources
Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature. [PDF]
Clin Case RepABSTRACT Euglycemic diabetic ketoacidosis (euDKA) is an uncommon but potentially life‐threatening complication that may arise in patients treated with incretin‐based therapies or Sodium–Glucose Cotransporter‐2 (SGLT2) inhibitors. We report a 41‐year‐old female with Type 1 Diabetes Mellitus (T1DM) who developed severe euDKA after initiating tirzepatide ...
Malik M +10 more
europepmc +2 more sources